- Teplizumab is now approved for NHS use in England and Wales.
- The immunotherapy delays symptomatic type 1 diabetes for up to three years.
- Eligible patients include adults and children aged eight and above.
The NHS in England and Wales will now provide teplizumab, an immunotherapy targeting stage 2 pre-symptomatic type 1 diabetes. This drug is administered via 14 consecutive daily intravenous drips. It postpones the onset of the disease for three years, which is a significant shift from traditional care.
The treatment works by training the immune system to cease attacking cells in the pancreas. Dosages are scaled up gradually over the two week course. This is the first non-insulin breakthrough in over 100 years, moving clinical focus toward the root cause of the condition.
Teplizumab delays onset of symptomatic type 1 diabetes
Nice has approved this for patients aged eight and older. By delaying stage 3, patients avoid the relentless demands of lifelong management. Children can reach key developmental milestones before starting insulin which has been the only other option for 105 years.
The drug produced by Sanofi, is not a cure. However it is viewed as a shift toward prevention. «Today’s landmark approval of teplizumab marks the start of a new age of type 1 diabetes treatment», stated the research director at Diabetes UK.
Early detection is critical for unlocking these clinical benefits. A confidential discounted price was agreed by Sanofi with NHS England. The evaluation by Nice was described as rigorous and transparent to balance taxpayer value with patient clinical benefit.
The chief executive of Breakthrough T1D called it an incredible moment. «For the first time, we have an immunotherapy that can delay the onset of symptomatic type 1 diabetes», they noted. Access must now be fair and equitabel for all eligible patients.
